Diagnostic and Prognostic Value of Serum Tissue Polypeptide Antigen in Advanced Lung Cancer


Lung cancer is a lethal malignancy, however, no serum marker is routinely recommended till now. Prospectively two groups of patients included: Group I: Patients with advanced lung cancer. Group II: patients with benign lung disease as control. Serum Tissue Polypeptide Antigen (TPA) levels were measured by ELISA technique before the first line chemotherapy. The TPA cutoff taken was 1800 pg./ml. End points were comparison of high TPA in cases and controls and correlation between high TPA and disease progression (PD), progression free survival (PFS) and overall survival (OS). 30 patients with advanced lung cancer (16 non-small and 14 small cell lung cancer) and 15 patients with benign lung disease were included and followed up during the period from October 2008 to October 2011 with median follow-up of 1.5 years. High TPA was found in 50% of lung cancer cases compared to 26% in controls (p = 0.014). High TPA was found in 64% of cases showing PD versus 36% normal TPA (p = 0.08). 1 year PFS in high TPA was 32% versus 39% in normal TPA, (p = 0.2). 1 year OS in high TPA was 46% versus 73% in normal TPA (p = 0.6). Serum TPA is a potential marker for advanced lung cancer.

Share and Cite:

El Bastawisy, A. , El Azzouny, M. , Mohamed, G. , Allah, A. and Behiry, E. (2014) Diagnostic and Prognostic Value of Serum Tissue Polypeptide Antigen in Advanced Lung Cancer. Journal of Cancer Therapy, 5, 231-237. doi: 10.4236/jct.2014.53030.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Buccheri, G. and Ferrigno, D. (2001) Lung Tumor Markers of Cytokeratin Origin: An Overview. Lung Cancer, 34, S65-S69.
[2] Lothgens, M. and Schlegel, G. (1983) Combined Use of Carcinoembryonic Antigen and Tissue Polypeptide Antigen in Oncologic Therapy and Surveillance. Cancer Detect Prevent, 6, 51.
[3] Holyoke, D. and Chu, T.M. (1997) Tissue Polypeptide Antigen. In: Herberman, R.B. and Mclntire, K.R., Eds., Immune-Diagnosis of Cancer, Dekker, New York, 513-521.
[4] Rapellino, M., Pecchio, F., Baldi, S., Scappaticci, E. and Cavallo, A. (2003) Clinical Utility of Tissue Polypeptide Antigen Determination in Lung Cancer Management. Anticancer Research, 15, 1065-1070.
[5] Haga, E. (2003) Tissue Polypeptide Antigen in Serum and Tissue in Patients with Lung Cancer. Nihon Kyōbu Shikkan Gakkai zasshi, 28, 595-604.
[6] Huang, M.-S., Jong, S.-B., Tsai, M.-S., Lin, M.-S., Chong, I.-W., Lin, H.-C. and Hwang, J.-J. (1997) Comparison of Cytokeratin Fragment 19 (CYFRA 21-1), Tissue Polypeptide Antigen (TPA) and Carcinoembryonic Antigen (CEA) as Tumour Markers in Bronchogenic Carcinoma. Respiratory Medicine, 91, 135-142.
[7] Foa, P., Fornier, M., Miceli, R., Seregni, E., Santambrogio, L., Nosotti, M., Cataldo, I., Sala, M., Caldiera, S. and Bombardieri, E. (2011) Tumor Markers CEA, NSE, SCC, TPA and CYFRA 21.1 in Resectable Non-Small Cell Lung Cancer. Anticancer Research, 19, 3613-3618.
[8] Kulpa, J., Wójcik, E., Radkowski, A., Kolodziejski, L. and Stasik, Z. (2011) CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in Patients with Squamous Cell Lung Cancer and in Chemical Industry Workers as a Reference Group. Anticancer Research, 20, 5035-5040.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.